Testolactone treatment of precocious puberty in McCune-Albright syndrome

C. M. Foster, O. H. Pescovitz, F. Comite, P. Feuillan, T. Shawker, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.

Original languageEnglish (US)
Pages (from-to)254-257
Number of pages4
JournalActa Endocrinologica
Volume109
Issue number2
StatePublished - 1985
Externally publishedYes

Fingerprint

Testolactone
Polyostotic Fibrous Dysplasia
Precocious Puberty
Aromatase Inhibitors
Menstruation
Therapeutics
Gonadotropins
Estradiol
Bone and Bones
Serum

ASJC Scopus subject areas

  • Endocrinology

Cite this

Foster, C. M., Pescovitz, O. H., Comite, F., Feuillan, P., Shawker, T., Loriaux, D. L., & Cutler, G. B. (1985). Testolactone treatment of precocious puberty in McCune-Albright syndrome. Acta Endocrinologica, 109(2), 254-257.

Testolactone treatment of precocious puberty in McCune-Albright syndrome. / Foster, C. M.; Pescovitz, O. H.; Comite, F.; Feuillan, P.; Shawker, T.; Loriaux, Donald (Lynn); Cutler, G. B.

In: Acta Endocrinologica, Vol. 109, No. 2, 1985, p. 254-257.

Research output: Contribution to journalArticle

Foster, CM, Pescovitz, OH, Comite, F, Feuillan, P, Shawker, T, Loriaux, DL & Cutler, GB 1985, 'Testolactone treatment of precocious puberty in McCune-Albright syndrome', Acta Endocrinologica, vol. 109, no. 2, pp. 254-257.
Foster CM, Pescovitz OH, Comite F, Feuillan P, Shawker T, Loriaux DL et al. Testolactone treatment of precocious puberty in McCune-Albright syndrome. Acta Endocrinologica. 1985;109(2):254-257.
Foster, C. M. ; Pescovitz, O. H. ; Comite, F. ; Feuillan, P. ; Shawker, T. ; Loriaux, Donald (Lynn) ; Cutler, G. B. / Testolactone treatment of precocious puberty in McCune-Albright syndrome. In: Acta Endocrinologica. 1985 ; Vol. 109, No. 2. pp. 254-257.
@article{d4aaaf107e814ff3823fbf6d401e2fcf,
title = "Testolactone treatment of precocious puberty in McCune-Albright syndrome",
abstract = "Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.",
author = "Foster, {C. M.} and Pescovitz, {O. H.} and F. Comite and P. Feuillan and T. Shawker and Loriaux, {Donald (Lynn)} and Cutler, {G. B.}",
year = "1985",
language = "English (US)",
volume = "109",
pages = "254--257",
journal = "Acta Endocrinology",
issn = "0001-5598",
publisher = "Munksgaard International Publishers",
number = "2",

}

TY - JOUR

T1 - Testolactone treatment of precocious puberty in McCune-Albright syndrome

AU - Foster, C. M.

AU - Pescovitz, O. H.

AU - Comite, F.

AU - Feuillan, P.

AU - Shawker, T.

AU - Loriaux, Donald (Lynn)

AU - Cutler, G. B.

PY - 1985

Y1 - 1985

N2 - Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.

AB - Current medical and surgical therapies of precocious puberty in McCune-Albright syndrome are often unsatisfactory. We used an aromatase inhibitor, testolactone, to treat precocious puberty in a girl with McCune-Albright syndrome. This child was unresponsive to 28 weeks of treatment with the long-acting agonist of LRH, D-trp6-pro9-NEt-LRH. During testolactone therapy, menses ceased, bone age advancement and height velocity diminished, and plasma oestradiol levels were suppressed. Serum gonadotrophin levels remained in the prepubertal range. Testolactone may be an effective therapy of precocious puberty in girls with McCune-Albright syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0021829245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021829245&partnerID=8YFLogxK

M3 - Article

C2 - 3925675

AN - SCOPUS:0021829245

VL - 109

SP - 254

EP - 257

JO - Acta Endocrinology

JF - Acta Endocrinology

SN - 0001-5598

IS - 2

ER -